Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigator Site
1192
mi
from 02139
Clearwater, FL
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigator Site
1192
mi
from 02139
Clearwater, FL
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
1180
mi
from 02139
Jupiter, FL
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
1180
mi
from 02139
Jupiter, FL
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
929
mi
from 02139
Decatur, GA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
929
mi
from 02139
Decatur, GA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigator Site
1304
mi
from 02139
Topeka, KA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigator Site
1304
mi
from 02139
Topeka, KA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
1414
mi
from 02139
Wichita, KA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
1414
mi
from 02139
Wichita, KA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
1356
mi
from 02139
Metairie, LA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
1356
mi
from 02139
Metairie, LA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
1417
mi
from 02139
Opelousas, LA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
1417
mi
from 02139
Opelousas, LA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
645
mi
from 02139
Flint, MI
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
645
mi
from 02139
Flint, MI
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
614
mi
from 02139
Troy, MI
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
614
mi
from 02139
Troy, MI
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
1253
mi
from 02139
Jackson, MS
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
1253
mi
from 02139
Jackson, MS
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
2105
mi
from 02139
Missoula, MT
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
2105
mi
from 02139
Missoula, MT
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
222
mi
from 02139
Freehold, NJ
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
222
mi
from 02139
Freehold, NJ
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
714
mi
from 02139
Hickory, NC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
714
mi
from 02139
Hickory, NC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
705
mi
from 02139
Dayton, OH
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
705
mi
from 02139
Dayton, OH
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
532
mi
from 02139
Willoughby Hills, OH
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
532
mi
from 02139
Willoughby Hills, OH
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigational Site
818
mi
from 02139
Charleston, SC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigational Site
818
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
790
mi
from 02139
Columbia, SC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
790
mi
from 02139
Columbia, SC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
853
mi
from 02139
Varnville, SC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
853
mi
from 02139
Varnville, SC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
712
mi
from 02139
Bristol, TN
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
712
mi
from 02139
Bristol, TN
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
954
mi
from 02139
Clarksville, TN
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
954
mi
from 02139
Clarksville, TN
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
732
mi
from 02139
Johnson City, TN
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
732
mi
from 02139
Johnson City, TN
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
595
mi
from 02139
Danville, VA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
595
mi
from 02139
Danville, VA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
465
mi
from 02139
Newport News, VA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
465
mi
from 02139
Newport News, VA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
10088
mi
from 02139
Darlinghurst,
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
10088
mi
from 02139
Darlinghurst,
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital of Alabama
1049
mi
from 02139
Birmingham, AL
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital of Alabama
1049
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Phoenix Children's Hospital
2288
mi
from 02139
Phoenix, AZ
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Phoenix Children's Hospital
2288
mi
from 02139
Phoenix, AZ
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Arkansas Children's Hospital Research Institute
1255
mi
from 02139
Little Rock, AR
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Arkansas Children's Hospital Research Institute
1255
mi
from 02139
Little Rock, AR
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Connecticut Children's Medical Center
91
mi
from 02139
Hartford, CT
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Connecticut Children's Medical Center
91
mi
from 02139
Hartford, CT
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Childrens National Medical Center
392
mi
from 02139
Washington,
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Childrens National Medical Center
392
mi
from 02139
Washington,
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Emory University School of Medicine
929
mi
from 02139
Atlanta, GA
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Emory University School of Medicine
929
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Comer Children's Hospital University of Chicago
845
mi
from 02139
Chicago, IL
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Comer Children's Hospital University of Chicago
845
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
University of Louisville Research Foundation, Inc.
821
mi
from 02139
Louisville, KY
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
University of Louisville Research Foundation, Inc.
821
mi
from 02139
Louisville, KY
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Joseph M. Sanzari Children's Hospital
183
mi
from 02139
Hackensack, NJ
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Joseph M. Sanzari Children's Hospital
183
mi
from 02139
Hackensack, NJ
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital at Montefiore
176
mi
from 02139
Bronx, NY
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital at Montefiore
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Cohen Children's Medical Center of NY
174
mi
from 02139
New Hyde Park, NY
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Cohen Children's Medical Center of NY
174
mi
from 02139
New Hyde Park, NY
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Cincinnati Children's Hospital Medical Center
734
mi
from 02139
Cincinnati, OH
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Cincinnati Children's Hospital Medical Center
734
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Cleveland Clinic Foundation
544
mi
from 02139
Cleveland, OH
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Cleveland Clinic Foundation
544
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Medical University of South Carolina
819
mi
from 02139
Charleston, SC
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Medical University of South Carolina
819
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital of Wisconsin
859
mi
from 02139
Milwaukee, WI
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital of Wisconsin
859
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Associates, PC
1049
mi
from 02139
Birmingham, AL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Associates, PC
1049
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Associates Of North Alabama, P.C.
986
mi
from 02139
Huntsville, AL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Associates Of North Alabama, P.C.
986
mi
from 02139
Huntsville, AL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Medvin Clinical Research
2569
mi
from 02139
Covina, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Medvin Clinical Research
2569
mi
from 02139
Covina, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Desert Medical Advances
2504
mi
from 02139
Palm Desert, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Desert Medical Advances
2504
mi
from 02139
Palm Desert, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
San Diego Arthritis Medical Clinic
2576
mi
from 02139
San Diego, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
San Diego Arthritis Medical Clinic
2576
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Millennium Research
1060
mi
from 02139
Ormond Beach, FL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Millennium Research
1060
mi
from 02139
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
The Arthritis Center
1182
mi
from 02139
Palm Harbor, FL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
The Arthritis Center
1182
mi
from 02139
Palm Harbor, FL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Klein & Associates MD, PA.
392
mi
from 02139
Hagerstown, MD
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Klein & Associates MD, PA.
392
mi
from 02139
Hagerstown, MD
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Clinical Pharmacology Study Group
36
mi
from 02139
Worcester, MA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Clinical Pharmacology Study Group
36
mi
from 02139
Worcester, MA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
St. Paul Rheumatology, PA
1112
mi
from 02139
Eagan, MN
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
St. Paul Rheumatology, PA
1112
mi
from 02139
Eagan, MN
Click here to add this to my saved trials